Table 2

The model-based individualised dosing table for busulfan, aiming for a myeloablative (AUCday0–4 of 90 mg*h/L in combination with fludarabine), compared with the approved dose in the summary of product characteristics (SPC)

Body weight kgModel-based individualised dosing nomogramApproved dose in SPC
Myeloablative dose 4 days, 1dd, mg/kg
target AUCday0–4 90 mg*h/La
4 days, 1dd, mg/kg
Dose (mg)Dose (mg/kg)± % deviation of target AUCDose (mg/kg)± % deviation of target AUC
3113.804.05
5244.704.0−15
7365.104.0−22
8415.204.0−23
9475.204.8−8
11585.204.8−9
13685.204.8−8
15775.104.8−6
16815.104.4−13
20974.904.4−9
231084.703.8−19
251154.603.8−17
301304.303.8−12
351434.103.2−22
401563.903.2−18
451673.703.2−14
501773.503.2−10
551873.403.2−6
601953.303.2−2
652043.103.22
  • Printed with permission from Bartelink IH, van Kesteren C, Boelens JJ, et al. Predictive performance of a busulfan pharmacokinetic model in children and young adults. Therapeutic Drug Monitoring 2012;34:574–83.